SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Co-Diagnostics,
Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that
Co-Diagnostics will be presenting at the H.C. Wainwright & Co.
2022 Global Investment Conference, being held in-person and
virtually on May 23-26 in
Miami, Florida.
Dwight Egan, Company CEO, will be
conducting a presentation discussing recent Company performance as
well as its forthcoming Co-Dx PCR Home Diagnostic Platform. The
presentation can be accessed by clicking here or through the
Events and Webcasts section of the Co-Diagnostics website on
May 25, 2022 at 1:30 PM Eastern Time, for institutional investors
and industry professionals who have registered for the
event.
Dwight Egan, Co-Diagnostics Chief
Executive Officer, remarked "Florida has represented an important market
for Co-Dx since the early days of the COVID-19 pandemic, with
several world-class distributors and laboratory facilities
operating across the state contributing over $28 million dollars of revenue. Our mosquito
abatement vertical has also grown steadily in the state since 2019,
with additional full laboratory installations taking place in
Florida and the surrounding region
this year. We are looking forward to the opportunity to communicate
our past success and future ambitions with our investor base at the
H.C. Wainwright conference in Miami next week."
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA) that are
subject to a number of risks and uncertainties. Risks and
uncertainties that may cause such differences include, among other
things: our products may not prove to be as effective as other
products currently being commercialized or to be commercialized in
the future by competitors; risks inherent in manufacturing and
scaling up to commercial quantities while maintaining quality
controls; the uncertainties inherent in new product development,
including the cost and time required to gain regulatory clearance
for such product and to commercialize such product(s);and, market
acceptance of our products once commercialized. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations, and beliefs. There can be no assurance that any of
the anticipated results will occur on a timely basis or at all due
to certain risks and uncertainties, a discussion of which can be
found in the Risk Factors disclosure in our Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 25, 2021, and in our other
filings with the SEC. The Company does not undertake any obligation
to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by
applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-hc-wainwright-2022-global-investment-conference-on-may-23-26-301551009.html
SOURCE Co-Diagnostics